Uropathogenic Escherichia coli Superinfection Enhances the Severity of Mouse Bladder Infection

PLoS Pathogens

Volumn 11, Issue 1, 2015, Pages 1-12

  Schwartz, Drew J ^a   Conover, Matt S ^a   Hannan, Thomas J ^b   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 11; CXCL1 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOLYSIN; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL SUPERINFECTION; BACTERIURIA; BLADDER DISEASE; COLONY FORMING UNIT; CONTROLLED STUDY; GENETIC ANALYSIS; INTERSTITIAL CYSTITIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RISK FACTOR; SCANNING ELECTRON MICROSCOPY; UPREGULATION; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; BLADDER; C3H MOUSE; C57BL MOUSE; COMPLICATION; CYSTITIS; DISEASE COURSE; DISEASE MODEL; ESCHERICHIA COLI INFECTION; FEMALE; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SUPERINFECTION; URINARY TRACT INFECTION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MURINAE; MUS;

ANIMALS; CYSTITIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ESCHERICHIA COLI INFECTIONS; FEMALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; SUPERINFECTION; URINARY BLADDER; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84923852035     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004599     Document Type: Article

References (72)

1. Foxman B, (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49: 53–70.
2. Rosenberg M, (1999) Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents 11: 247–251 discussion 261–244.
3. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD, (2000) Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10: 509–515.
4. Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, et al. (2000) Risk factors for second urinary tract infection among college women. American journal of epidemiology 151: 1194–1205.
5. Czaja CA, Stamm WE, Stapleton AE, Roberts PL, Hawn TR, et al. (2009) Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women. The Journal of infectious diseases 200: 528–536.
6. Stamm WE, McKevitt M, Roberts PL, White NJ, (1991) Natural history of recurrent urinary tract infections in women. Rev Infect Dis 13: 77–84.
7. Stamm WE, (2002) Scientific and clinical challenges in the management of urinary tract infections. Am J Med 113 Suppl 1A: 1S–4S.
8. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB, (2007) Community-onset urinary tract infections: a population-based assessment. Infection 35: 150–153.
9. Ferry S, Holm S, Stenlund H, Lundholm R, Monsen T, (2004) The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scandinavian Journal of Infectious Diseases 36: 296–301.
10. Mabeck CE, (1972) Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgraduate medical journal 48: 69–75.
11. Ejrnaes K, Sandvang D, Lundgren B, Ferry S, Holm S, et al. (2006) Pulsed-Field Gel Electrophoresis Typing of Escherichia coli Strains from Samples Collected before and after Pivmecillinam or Placebo Treatment of Uncomplicated Community-Acquired Urinary Tract Infection in Women. Journal of Clinical Microbiology 44: 1776–1781.
12. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI, (2009) Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: A meta-analysis of randomized controlled trials. Journal of Infection 58: 91–102.
13. Marschall J, Zhang L, Foxman B, Warren DK, Henderson JP, et al. (2012) Both host and pathogen factors predispose to Escherichia coli urinary-source bacteremia in hospitalized patients. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 54: 1692–1698.
14. Gupta K, Hooton TM, Stamm WE, (2005) Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. The Journal of antimicrobial chemotherapy 56: 243–246.
15. Gupta K, Sahm DF, Mayfield D, Stamm WE, (2001) Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 33: 89–94.
16. Bouchillon S, Hoban DJ, Badal R, Hawser S, (2012) Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009–2010. The open microbiology journal 6: 74–78.
17. Chen YH, Ko WC, Hsueh PR, (2012) The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 31: 1699–1704.
18. Buckley RM, JrMcGuckin M, MacGregor RR, (1978) Urine bacterial counts after sexual intercourse. N Engl J Med 298: 321–324.
19. Nicolle LE, Harding GK, Preiksaitis J, Ronald AR, (1982) The association of urinary tract infection with sexual intercourse. The Journal of infectious diseases 146: 579–583.
20. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, et al. (1996) A prospective study of risk factors for symptomatic urinary tract infection in young women. The New England journal of medicine 335: 468–474.
21. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ, (2007) Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4: e329.
22. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, et al. (2000) Risk factors for recurrent urinary tract infection in young women. The Journal of infectious diseases 182: 1177–1182.
23. Foxman B, Geiger AM, Palin K, Gillespie B, Koopman JS, (1995) First-time urinary tract infection and sexual behavior. Epidemiology 6: 162–168.
24. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC, (2011) Population Dynamics and Niche Distribution of Uropathogenic Escherichia coli during Acute and Chronic Urinary Tract Infection. Infect Immun 79: 4250–4259.
25. Walters MS, Lane MC, Vigil PD, Smith SN, Walk ST, et al. (2011) Kinetics of Uropathogenic Escherichia coli Metapopulation Movement during Urinary Tract Infection. mBio 3: e00303–00311.
26. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, et al. (2012) Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 36: 616–648.
27. Schwartz DJ, Hultgren SJ (2012) Uropathogenic Escherichia coli Virulence and Gene Regulation. In: Vasil ML, Darwin AJ, editors. Regulation of Bacterial Virulence. Washington, D.C.: ASM Press. pp. 135–155.
28. Wu XR, Sun TT, Medina JJ, (1996) In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci U S A 93: 9630–9635.
29. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, et al. (1998) Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282: 1494–1497.
30. Eto DS, Jones TA, Sundsbak JL, Mulvey MA, (2007) Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog 3: e100.
31. Song J, Bishop BL, Li G, Grady R, Stapleton A, et al. (2009) TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 106: 14966–14971.
32. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, et al. (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301: 105–107.
33. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, et al. (2004) Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 101: 1333–1338.
34. Justice SS, Hunstad DA, Seed PC, Hultgren SJ, (2006) Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci USA 103: 19884–19889.
35. Robino L, Scavone P, Araujo L, Algorta G, Zunino P, et al. (2013) Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathogens and Disease 68: 78–81.
36. Garofalo CK, Hooton TM, Martin SM, Stamm WE, Palermo JJ, et al. (2007) Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infection and Immunity 75: 52–60.
37. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ, (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6.
38. Hopkins WJ, Gendron-Fitzpatrick A, Balish E, Uehling DT, (1998) Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infection and Immunity 66: 2798–2802.
39. Kline KA, Schwartz DJ, Gilbert NM, Hultgren SJ, Lewis AL, (2012) Immune Modulation by Group B Streptococcus Influences Host Susceptibility to Urinary Tract Infection by Uropathogenic Escherichia coli. Infection and Immunity 80: 4186–4194.
40. Mysorekar IU, Hultgren SJ, (2006) Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 103: 14170–14175.
41. Schilling JD, Lorenz RG, Hultgren SJ, (2002) Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infection and Immunity 70: 7042–7049.
42. Schlager TA, LeGallo R, Innes D, Hendley JO, Peters CA, (2011) B Cell Infiltration and Lymphonodular Hyperplasia in Bladder Submucosa of Patients With Persistent Bacteriuria and Recurrent Urinary Tract Infections. JURO 186: 2359–2364.
43. Stemler KM, Crock LW, Lai HH, Mills JC, Gereau RW, et al. (2013) Protamine sulfate induced bladder injury protects from distention induced bladder pain. J Urol 189: 343–351.
44. Rudick CN, Billips BK, Pavlov VI, Yaggie RE, Schaeffer AJ, et al. (2010) Host-pathogen interactions mediating pain of urinary tract infection. The Journal of infectious diseases 201: 1240–1249.
45. Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, et al. (2014) Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBIOM 1–12.
46. Guiton PS, Hannan TJ, Ford B, Caparon MG, Hultgren SJ, (2013) Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infection and Immunity 81: 329–339.
47. Chen SL, Hung CS, Pinkner JS, Walker JN, Cusumano CK, et al. (2009) Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proceedings of the National Academy of Sciences of the United States of America 106: 22439–22444.
48. Schwartz DJ, Kalas V, Pinkner JS, Chen SL, Spaulding CN, et al. (2013) Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proceedings of the National Academy of Sciences 110: 15530–15537.
49. Phan G, Remaut H, Wang T, Allen WJ, Pirker KF, et al. (2011) Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 474: 49–53.
50. Le Trong I, Aprikian P, Kidd BA, Forero-Shelton M, Tchesnokova V, et al. (2010) Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Cell 141: 645–655.
51. Nicholson TF, Watts KM, Hunstad DA, (2009) OmpA of uropathogenic Escherichia coli promotes postinvasion pathogenesis of cystitis. Infection and Immunity 77: 5245–5251.
52. Anderson GG, Goller CC, Justice S, Hultgren SJ, Seed PC, (2010) Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infection and Immunity 78: 963–975.
53. Dhakal BK, Mulvey MA, (2012) The UPEC Pore-Forming Toxin α-Hemolysin Triggers Proteolysis of Host Proteins to Disrupt Cell Adhesion, Inflammatory, and Survival Pathways. Cell Host and Microbe 11: 58–69.
54. Gur C, Coppenhagen-Glazer S, Rosenberg S, Yamin R, Enk J, et al. (2013) Natural Killer Cell-Mediated Host Defense against Uropathogenic E. coli Is Counteracted by Bacterial HemolysinA-Dependent Killing of NK Cells. Cell Host & Microbe 14: 664–674.
55. Dhakal BK, Mulvey MA, (2012) The UPEC Pore-Forming Toxin α-Hemolysin Triggers Proteolysis of Host Proteins to Disrupt Cell Adhesion, Inflammatory, and Survival Pathways. Cell Host and Microbe 11: 58–69.
56. Ahn H, Kim J, Jeung E-B, Lee G-S, (2014) Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology 219: 315–322.
57. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H, (1990) Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 143: 139–142.
58. Eto DS, Gordon HB, Dhakal BK, Jones TA, Mulvey MA, (2008) Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells. Cellular Microbiology 10: 2553–2567.
59. Mossman KL, Mian MF, Lauzon NM, Gyles CL, Lichty B, et al. (2008) Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand. J Immunol 181: 6702–6706.
60. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE, (2012) The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res 40: D881–886.
61. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
62. Huang da W, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1–13.
63. Thumbikat P, Waltenbaugh C, Schaeffer AJ, Klumpp DJ, (2006) Antigen-specific responses accelerate bacterial clearance in the bladder. Journal of immunology (Baltimore, Md: 1950) 176: 3080–3086.
64. Hooton TM, (2001) Recurrent urinary tract infection in women. Int J Antimicrob Agents 17: 259–268.
65. Chen SL, Wu M, Henderson JP, Hooton TM, Hibbing ME, et al. (2013) Genomic Diversity and Fitness of E. coli Strains Recovered from the Intestinal and Urinary Tracts of Women with Recurrent Urinary Tract Infection. Science Translational Medicine 5: 184ra160.
66. Mabbett AN, Ulett GC, Watts RE, Tree JJ, Totsika M, et al. (2009) Virulence properties of asymptomatic bacteriuria Escherichia coli. International journal of medical microbiology: IJMM 299: 53–63.
67. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, et al. (2011) Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors. Sci Transl Med 3: 109ra115.
68. Schwardt O, Rabbani S, Hartmann M, Abgottspon D, Wittwer M, et al. (2011) Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem 19: 6454–6473.
69. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, et al. (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. Journal of medicinal chemistry 53: 8627–8641.
70. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, et al. (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53: 4779–4792.
71. Wright KJ, Seed PC, Hultgren SJ, (2005) Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infection and Immunity 73: 7657–7668.
72. Hung C-S, Dodson KW, Hultgren SJ, (2009) A murine model of urinary tract infection. Nature protocols 4: 1230–1243.